LENZ Therapeutics, Inc.

Good morning, ladies and gentlemen, and welcome to the Lenz Therapeutics Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following prepared remarks from management with accompanying slides, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Dan Chevallard, Chief Financial Officer, please go ahead.

Thank you, Tina. Good morning and thank you for joining us today. My name is Dan Chevallard, Chief Financial Officer of Lenz Therapeutics. We are joined today by Evert Schimmelpennink, our President and Chief Executive Officer, Shawn Olsson, our Chief Commercial Officer, and Dr. Marc Odrich, our Chief Medical Officer. Before we begin, I would like to remind you that this call will contain forward-looking statements regarding LENZ's future expectations, plans, prospects, corporate strategy, regulatory and commercial plans and expectations, cash runway projections, and performance. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors and risks, including those discussed in our filings with the SEC and which can also be found on our website. In addition, any forward-looking statements represent only our views as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. The company encourages you to consult the risk factors contained in RST filings for additional detail. With that, I'll now turn the call over to Abe.

Thank you, Dan. Good morning, everyone. Today's results mark an important step forward for Lens and VIS. In the third quarter, we saw more than 50% growth in both product revenue and total prescriptions, with strong momentum continuing into the fourth quarter. On October 1st, we marked the one-year anniversary of the VIS launch. Over the past year, we've built important foundations, gained valuable insights into what drives reductions, and importantly, drove encouraging momentum from our consumer-focused initiatives. This last quarter, we continue to see that consumer demand generation is a key driver of growth. Expanding our Tidal Reading Glasses campaign to national TV enabled us to reach a broader group of consumers with a clear message around alternatives to reading glasses. Our newly established telehealth channel also gives interested consumers a convenient path to evaluation by an independent, licensed eye care professional and, if appropriate, a prescription with home delivery. Together, these initiatives have helped establish a more seamless path from awareness to evaluation, treatment, and continued use. And as I mentioned, the results were more than 50% growth in product revenue and total prescriptions in the third quarter, with strong momentum carrying into the early weeks of Q4. We have built a strong foundation with eye care professionals. Vis awareness now exceeds 90% with more than 15,000 prescribing ECPs. At the same time, our launch experience has shown that physician events alone is not sufficient to drive adoption at the pace we want. The strongest growth response has come when consumer demand generation is paired with convenient access. All of this is giving us greater clarity on the commercial model best positioned to support durable growth in this category. Based on what we have learned, we announced a strategic reorganization designed to align LENZ with this consumer-led commercial model. Going forward, consumer marketing will be the emphasis of our U.S. commercial strategy, with a much smaller and more focused sales and medical team maintaining important KOL, ECP, and trade relationships. This is an evolution of our launch strategy, not a change in our commitment to LENZ. The reorganization concentrates our people and capital on the activities that are demonstrating the clearest connection to patient acquisition and sales growth. It also creates a more efficient structure for the business we are building. As part of this transition, we expect our organization to move to approximately 40 employees, and we expect overall operating expense to decrease by more than 50%. We are targeting 2027 operating expenses of approximately $70 to $75 million, with more than 70% of our projected spend allocated to our consumer-driven sales and marketing strategy. We strongly believe this focused model gives us the opportunity to reach more patients, expanding this emerging category, and building a durable business. With that, I will hand it over to Shawn, who will provide more detail on our commercial execution. Thank you, Abe.